Literature DB >> 30879988

Host immunogenetics in tick-borne encephalitis virus infection-The CCR5 crossroad.

Joel Henrique Ellwanger1, José Artur Bogo Chies2.   

Abstract

The human Tick-borne encephalitis virus (TBEV) infection is a complex event encompassing factors derived from the virus itself, the vectors, the final host, and the environment as well. Classically, genetic traits stand out among the human factors that modify the susceptibility and progression of infectious diseases. However, and although this is a changing scenario, studies evaluating the genetic factors that affect the susceptibility specifically to TBEV infection and TBEV-related diseases are still scarce. There are already some interesting pieces of evidence showing that some genes and polymorphisms have a real impact on TBEV infection. Also, the inflammatory processes involving tick-human interactions began to be understood in greater detail. This review focuses on the immunogenetic and inflammatory aspects concerning tick-host interactions, TBEV infections, and tick-borne encephalitis. Of note, it has been described that polymorphisms in CD209, GSTM1, IL-10, IL-28B, MMP9, OAS2, OAS3, and TLR3 have a statistically significant impact on TBEV infection. Besides, CCR5, its ligands, and the CCR5Δ32 genetic variant seem to have a very important influence on the infection and its immune responses. Taking this information into consideration, a special discussion regarding the effects of CCR5 on TBEV infection and tick-borne encephalitis will be presented. Emerging topics (such as exosomes, evasins, and CCR5 blockers) involving immunological and inflammatory aspects of TBEV-human interactions will also be addressed. Lastly, the current picture of TBEV infection and the importance to address the TBEV-associated problems through the One Health perspective will be discussed.
Copyright © 2019 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  CCR5; CCR5Δ32; Genetics; Inflammation; TBEV; Tick; Tick-borne encephalitis

Mesh:

Substances:

Year:  2019        PMID: 30879988     DOI: 10.1016/j.ttbdis.2019.03.005

Source DB:  PubMed          Journal:  Ticks Tick Borne Dis        ISSN: 1877-959X            Impact factor:   3.744


  6 in total

1.  CCR5 deficiency impairs CD4+ T-cell memory responses and antigenic sensitivity through increased ceramide synthesis.

Authors:  Ana Martín-Leal; Raquel Blanco; Josefina Casas; María E Sáez; Elena Rodríguez-Bovolenta; Itziar de Rojas; Carina Drechsler; Luis Miguel Real; Gemma Fabrias; Agustín Ruíz; Mario Castro; Wolfgang Wa Schamel; Balbino Alarcón; Hisse M van Santen; Santos Mañes
Journal:  EMBO J       Date:  2020-06-11       Impact factor: 11.598

Review 2.  Extracellular vesicles in host-pathogen interactions and immune regulation - exosomes as emerging actors in the immunological theater of pregnancy.

Authors:  Valéria de Lima Kaminski; Joel Henrique Ellwanger; José Artur Bogo Chies
Journal:  Heliyon       Date:  2019-08-31

Review 3.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

Review 4.  Recent Progress on Tick-Borne Animal Diseases of Veterinary and Public Health Significance in China.

Authors:  Weijuan Jia; Si Chen; Shanshan Chi; Yunjiang He; Linzhu Ren; Xueli Wang
Journal:  Viruses       Date:  2022-02-09       Impact factor: 5.048

5.  Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway.

Authors:  Yingli Zhang; Rongrong Liang; Aicen Xie; Wenqian Shi; Huarong Huang; Yingqiang Zhong
Journal:  Mediators Inflamm       Date:  2020-04-28       Impact factor: 4.711

Review 6.  CCR5Δ32 in Brazil: Impacts of a European Genetic Variant on a Highly Admixed Population.

Authors:  Bruna Kulmann-Leal; Joel Henrique Ellwanger; José Artur Bogo Chies
Journal:  Front Immunol       Date:  2021-12-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.